Case report demonstrates durable partial response to everolimus in metastatic hepatic PEComa, indicating potential treatment efficacy.
We report a case of a 63-year-old male with metastatic hepatic PEComa harboring TSC2 and NF2 mutations who achieved a durable partial response to everolimus with only mild adverse effects. This case highlights the value of genomic profiling and the efficacy of mTOR inhibitors in hepatic PEComa management.
No takes yet. Share an insight, caveat, or question.
Thitvirachawat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: